Se­nior econ­o­mist and head of the De­part­ment of Eco­nom­ics at UWI St Au­gus­tine, Dr Daren Con­rad is cau­tion­ing that re­cent back­pay dis­burse­ments to pub­lic-sec­tor work­ers are un­like­ly ...

Cambridge, Massachusetts, Feb. 04, 2026 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease ...

JavaScript updates in 2026 focus on fixing long-standing issues instead of adding unnecessary complexity. Core features now handle iteration sets, async logic, and dates with fewer workarounds and ...

ProMIS Neurosciences ( (PMN)) has provided an announcement. On December 12, 2025, ProMIS Neurosciences Inc. announced it has regained compliance with Nasdaq’s $1.00 minimum bid price requirement, ...

Cambridge, Massachusetts, Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) ...

Cambridge, Massachusetts, Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody ...

Cambridge, Massachusetts, Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s ...

• ProMIS Neurosciences, Inc. shares fell 19% to $0.34 following a one-for-twenty-five reverse stock split. • The company reported a significant loss of $0.24 per share in Q3, missing expectations and ...

• ProMIS Neurosciences Inc. (PMN) shares rose 8.98% in pre-market trading to $0.3957 following the announcement of strong Q3 financial results, reflecting improved investor sentiment. • The company ...

JavaScript is a crucial web component and a building block for many web apps and websites. Sometimes users can accidentally disable JavaScript, but the browser settings can help you enable it again.

Investigators found that making a few changes to a common patient-reported outcomes assessment improved its validity in patients with Duchenne muscular dystrophy. A new customized version of a common ...